Evogene Ltd. (EVGN)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 312K | 314K | 334K | 347K |
| Gross Profit | 155K | (2.0M) | 204K | 141K |
| Operating Income | (2.7M) | (5.2M) | (3.1M) | (2.6M) |
| Net Income | 3.9M | (5.3M) | (5.9M) | (1.8M) |
| Diluted EPS | $0.44 | $-0.61 | $-0.60 | $-0.14 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.7M | 3.0M | 5.6M | 3.9M |
| Gross Profit | 766K | 1.5M | 3.2M | (241K) |
| Operating Income | (26.9M) | (22.2M) | (18.8M) | (14.0M) |
| Net Income | (26.6M) | (23.9M) | (16.5M) | (8.5M) |
| Diluted EPS | $-6.50 | $-5.20 | $-2.89 | $-1.08 |